Xeris Biopharma Holdings (XERS) Revenue (2020 - 2026)

Xeris Biopharma Holdings has reported Revenue for 7 years, with the latest figure at $83.1 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 38.27% year-over-year to $83.1 million; the trailing twelve-month figure through Mar 2026 stood at $314.9 million (up 41.47% YoY), and the FY2025 full-year result was $291.8 million, up 43.72% from the prior year.
• Revenue for Q1 2026 stood at $83.1 million, down from $85.8 million in the prior quarter.
• The five-year high for Revenue was $85.8 million in Q4 2025, with the low at $22.1 million in Q1 2022.
• Historically, Revenue has averaged $50.1 million across 5 years, with a median of $48.1 million in 2024.
• Annual changes were most pronounced in 2022 — Revenue jumped 184.15% — and 2024, when it grew 12.31%.
• Xeris Biopharma Holdings' Revenue stood at $33.1 million in 2022, then soared by 33.93% to $44.4 million in 2023, then jumped by 35.39% to $60.1 million in 2024, then surged by 42.78% to $85.8 million in 2025, then retreated by 3.12% to $83.1 million in 2026.
• The last three Revenue figures came in at $83.1 million (Q1 2026), $85.8 million (Q4 2025), and $74.4 million (Q3 2025), per Business Quant data.